<DOC>
	<DOCNO>NCT02547948</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy CD19-targeting CAR T Cells infusion B Cell Lymphoma .</brief_summary>
	<brief_title>CD19-targeting CAR T Cells B Cell Lymphoma</brief_title>
	<detailed_description>Chimeric antigen receptor ( CAR ) T cell target CD19 evaluate safety efficacy patient B cell lymphoma leukemia . The CAR consist CD19 target antibody scFv two intracellular signal domain derive CD3 zeta CD28 . Autologous T cell gene-engineered CAR gene use retrovirus vector . Prior T cell infusion , patient subject precondition treatment . After T cell infusion , patient evaluate 24 month adverse reaction , persistence CAR T cell efficacy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>1 . Relapsed refractory CD19+ Bcell lymphoma . 2 . Measurable disease . 3 . Performance status ECOG 02 . 4 . Age:1880 . 5 . Fertile females/males must consent use contraceptive participation trial . 6 . Signed informed consent 1 . Any significant medical psychiatric illness would prevent patient give informed consent follow study procedure . 2 . Patients primary CNS lymphoma . 3 . Known human immunodeficiency virus ( HIV ) infection . 4 . Active and/or severe infection ( e.g . tuberculosis , sepsis opportunistic infection , active hepatitis B virus ( HBV ) active hepatitis C virus ( HCV ) infection ) . 5 . Other serious underlie medical condition , , Investigator 's judgment , could impair ability patient . 6 . Treatment investigational product within 30 day prior enrollment , least 5 half life drug , long . 7 . Patients consent tissue blood sample store biobank . 8 . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>CD19</keyword>
	<keyword>CAR T Cells</keyword>
	<keyword>Lymphoma</keyword>
</DOC>